Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Olivia Thomas
06.28.18
A team of Pillsbury lawyers led by corporate partner Jonathan Russo advised ProZyme Inc. in connection with its sale to Agilent Technologies, Inc. Founded in 1990, ProZyme is a leading developer and manufacturer of glycan reagents, kits and standards required for efficient sample prep in the analysis of free glycans. Glycans play diverse roles in biotherapeutics, novel drug development, the study of bacterial physiology, and proteomics research.
The value of the transaction was not disclosed. The transaction is subject to customary closing conditions.
Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,200 people worldwide.
For more details about this transaction, click here.
The deal team advising ProZyme was led by Pillsbury Corporate & Securities partner Jonathan Russo and included partner Patrick Devine and associates Stephanie Langan and Patrick Mock. Partners Nora Burke (Tax) and Sarah Gajkowski (Intellectual Property), counsel Jessica Lutrin (Executive Compensation & Benefits) and special counsel Reza Zarghamee (Environmental) were also part of the team.